Get the Stockscreener App
6.85
21.26%
-1.85
After Hours:
6.81
-0.04
-0.58%
Scisparc Ltd stock is traded at $6.85, with a volume of 106.06K.
It is down -21.26% in the last 24 hours and up +24.09% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$8.70
Open:
$7.57
24h Volume:
106.06K
Relative Volume:
0.14
Market Cap:
$3.93M
Revenue:
$856.00K
Net Income/Loss:
$-12.56M
P/E Ratio:
-0.0296
EPS:
-231.4926
Net Cash Flow:
$-4.14M
1W Performance:
+28.52%
1M Performance:
+24.09%
6M Performance:
-1.03%
1Y Performance:
-86.69%
1-Day Range:
$6.61
$8.00
1-Week Range:
$4.76
$11.51
52-Week Range:
$2.98
$80.10
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
6.85 | 2.87M | 856.00K | -12.56M | -4.14M | -231.49 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Scisparc Ltd Stock (SPRC) Latest News
Scisparc Ltd (SPRC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Scisparc Ltd (SPRC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SciSparc shifts focus to agentic AI market - Investing.com
Scisparc Ltd (SPRC) Balance Sheet - TradingKey
Scisparc Ltd (SPRC) Institutional Confidence - TradingKey
SciSparc shifts focus to agentic AI market By Investing.com - Investing.com Canada
SciSparc targets agentic AI market and forms ad... - Pluang
Scisparc Ltd (SPRC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SciSparc Ltd. Targets Agentic AI Market and Plans Scientific Advisory Board for AI and Cybersecurity - Quiver Quantitative
SciSparc discusses agentic AI opportunities with several companies - Stock Titan
Scisparc Ltd (SPRC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Scisparc Ltd (SPRC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SciSparc Ltd. Revenue Breakdown – NASDAQ:SPRC - TradingView
SPRC|Scisparc Ltd|Price:5.330|Chg%:-0.390 - TradingKey
SciSparc Company Profile & Introduction - Moomoo
Scisparc Ltd (SPRC) Income Statement - TradingKey
SciSparc (SPRC) Stock Forecast & Analyst Ratings - Moomoo
SciSparc(SPRC) Stock Options Chain | Quotes & News - Moomoo
SciSparc Ltd. (Nasdaq: SPRC) starts Phase IIb SCI-110 trial for Tourette - Stock Titan
NeuroThera starts Phase IIb trial in Germany fo... - Pluang
SciSparc Subsidiary NeuroThera Initiates Phase IIb SCI-110 Clinical Trial Site at Hannover Medical School for Adult Tourette Syndrome - Quiver Quantitative
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb - GlobeNewswire
NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome - TheNewswire
Tourette treatment candidate SCI-110 enters testing at Hannover Medical School - Stock Titan
SciSparc (SPRC) Slips Over 7%: Support at $4.11 in Focus After Sharp DeclineWeak Sell Signals - dars.gov.et
SciSparc Ltd. (SPRC) details Alon Dayan RSUs and option in ownership update - Stock Titan
SciSparc Ltd. (SPRC) CEO Adler Oz updates Form 3 insider equity details - Stock Titan
SciSparc Ltd. (SPRC) director details RSU and option holdings in Form 3/A - Stock Titan
SciSparc Ltd. (SPRC) director revises Form 3, detailing RSU and option holdings - Stock Titan
SciSparc Ltd. (SPRC) CTO clarifies 5,528 RSU-linked shares and option terms - Stock Titan
SciSparc Ltd. (SPRC) director amends Form 3, details 3,649-share stake - Stock Titan
SciSparc Ltd. (SPRC) Tumbles 13.8% — Support Test in FocusRelative Volume - dars.gov.et
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
SciSparc (SPRC) Surges Over 10% as Trading Activity Picks UpOrder Block - dars.gov.et
SPRC Stock Price, Quote & Chart - ChartMill
NeuroThera Labs Announces Upsize to Private Placement - TheNewswire
NeuroThera Labs Announces C$5,000,000 Private Placement of Units - TheNewswire
SciSparc (SPRC) Drops 6.7% as Shares Approach Critical Support ZoneETF Creation Redemption - dars.gov.et
Form 144 SciSparc Ltd. For: 22 June By Investing.com - Investing.com Australia
[144] SciSparc Ltd. SEC Filing - Stock Titan
SciSparc (SPRC) Suffers Sharp Decline: Key Support Levels Under PressureVolume Breakout Ideas - dars.gov.et
Scisparc Ltd (SPRC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Scisparc Ltd (SPRC) Valuation: PE, PB & Fair Value Analysis - TradingKey
SPRC News | SCISPARC LTD (NASDAQ:SPRC) - ChartMill
Scisparc Ltd (SPRC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SciSparc Ltd. (SPRC) Slips 2.46% as Shares Test Near-Term Support at $7.92Long Setup Ideas - dars.gov.et
SciSparc Ltd. Ordinary Shares Stock Short Interest Rises to 66.94% - Moomoo
SciSparc Ltd.'s Equity Buyback announced on July 7, 2022, has expired. - marketscreener.com
Why is SciSparc stock skyrocketing on Thursday? - MSN
SciSparc more than doubles as NeuroThera wins conditional nod for CliniQuantum deal - MSN
NeuroThera completes acquisition of 54% stake in CliniQuantum - Investing.com UK
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Scisparc Ltd Stock (SPRC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shrem Itschak | Director |
Jun 01 '26 |
Sale |
10.00 |
462 |
4,620 |
10,596 |
2.44%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):